Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$47 Mln
P/E Ratio
--
P/B Ratio
3.13
Industry P/E
--
Debt to Equity
0
ROE
-0.71 %
ROCE
--
Div. Yield
0 %
Book Value
0.36
EPS
-0.29
CFO
$-25.01 Mln
EBITDA
$-26.00 Mln
Net Profit
$-79.25 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Anebulo Pharmaceuticals (ANEB)
| -32.14 | -27.85 | -25.97 | -59.14 | -35.76 | -- | -- |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Anebulo Pharmaceuticals (ANEB)
| -30.37 | -0.15 | -60.59 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product... candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas. Read more
Founder & Chairman
Dr. Joseph F. Lawler M.D., Ph.D.
Founder & Chairman
Dr. Joseph F. Lawler M.D., Ph.D.
Headquarters
Lakeway, TX
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Anebulo Pharmaceuticals Inc (ANEB) stood at $ 17 Mln as on 31-Dec-24
The share price of Anebulo Pharmaceuticals Inc (ANEB) is $1.14 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Anebulo Pharmaceuticals Inc (ANEB) has given a return of -35.76% in the last 3 years.
Anebulo Pharmaceuticals Inc (ANEB) has a market capitalisation of $ 47 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Anebulo Pharmaceuticals Inc (ANEB) is 3.13 times as on 25-Apr-2025, a 37% premium to its peers’ median range of 2.29 times.
Since, TTM earnings of Anebulo Pharmaceuticals Inc (ANEB) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Anebulo Pharmaceuticals Inc (ANEB) and enter the required number of quantities and click on buy to purchase the shares of Anebulo Pharmaceuticals Inc (ANEB).
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
The CEO & director of Dr. Joseph F. Lawler M.D., Ph.D.. is Anebulo Pharmaceuticals Inc (ANEB), and CFO & Sr. VP is Dr. Joseph F. Lawler M.D., Ph.D..
There is no promoter pledging in Anebulo Pharmaceuticals Inc (ANEB).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Anebulo Pharmaceuticals Inc. (ANEB) | Ratios |
|---|---|
|
Return on equity(%)
|
-81.68
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Anebulo Pharmaceuticals Inc (ANEB) was $0 Mln.
$0.06
(
